€0.54
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Defence Therapeutics Inc.
sharewise wants to provide you with the best news and tools for Defence Therapeutics Inc., so we directly link to the best financial data sources.
Financials
News
Defence Therapeutics Demonstrates Strong Preclinical In Vivo Efficacy Results Evaluation Accum-Kadcyla in Breast Cancer Models
Montreal, QC, Canada, November 4th, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), a leading biotechnology company specialized in drug delivery technologies, is pleased to
Defence to Present New Scientific Data on its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025
Montreal, QC, Canada, October 23rd, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), a leading biotechnology company specialized in drug delivery technologies, is pleased to
Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025
Montreal, QC, Canada, October 6th, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), a leading biotechnology company specialized in drug delivery technologies, is pleased to
Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations
Montreal, QC, Canada, October 2nd, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), a leading biotechnology company specialized in drug delivery technologies, is pleased to
Defence Therapeutics Appoints Dr. Amie Phinney as Director
Montreal, QC, Canada, September 16th, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), a leading biotechnology company specialized in drug delivery technologies, is pleased to
Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth
Montreal, QC, Canada, September 2nd, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”) (CSE: DTC) (FSE: DTC) (USOTC: DTCFF), a leading biotechnology company specialized in drug
Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology
Montreal, QC, Canada, June 9th, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a leading biotechnology company specializing in drug delivery
Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub
Montreal, QC, Canada, June 2nd, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a leading biotechnology company specializing in advanced
Defence Therapeutics to Attend Bio International Convention in Boston, June 2025
Montreal, QC, Canada, May 28th, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a Canadian biopharmaceutical company developing advanced